[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia-lymphoblastic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia-lymphoblastic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100557408","breath-analysis-for-the-detection-of-invasive-fungal-infections-100557408",false,"NCT06537726","Breath Analysis for the Detection of Invasive Fungal Infections","Real-time Breath Analysis for the Detection of Invasive Fungal Infections in Neutropenic High-risk Patients","REDEFINE","Inclusion Criteria:\n\n* Diagnosis of acute leukemia\n* Planned chemotherapy with a duration of hospitalisation of 2 weeks or longer\n* Neutropenia (\\\u003C500\u002Fµl) present at inclusion or planned chemotherapy with expected neutropenia (\\\u003C500\u002Fµl) for more than 7 days\n\nExclusion Criteria:\n\n* Unable to follow instructions for breath analysis\n* Anatomic abnormalities precluding the use of a mouthpiece for breath analysis","ALL","18 Years",{"count":20,"type":21},130,"ESTIMATED","OBSERVATIONAL","Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity.\n\nWith the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).",[25,26,27,28,29,30,31],"Leukemia","Leukemia, Myeloid","Leukemia, Lymphoblastic","Neutropenia","Chemotherapy-induced Neutropenia","Invasive Fungal Infections","Invasive Pulmonary Aspergillosis","RECRUITING","2025-04-09",{"date":35,"type":36},"2025-04-10","ACTUAL",{"date":38,"type":36},"2024-08-19",{"date":40,"type":21},"2027-10-31",{"name":42,"class":43},"University of Zurich","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100586747","triple-negative-adult-b-cell-acute-lymphoblastic-leukemia---trineg-all-100586747","NCT06919393","\"Triple Negative\" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL","\"Triple Negative\" Adult B-cell Acute Lymphoblastic Leukemia: Molecular Characterization, Identification and New Stratification","TRINEG-ALL","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study;\n* Patients with new diagnosis and\u002For relapse\u002Fs of primary or secondary B-ALL;\n* Negative for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements;\n* Participant is willing and able to give informed consent for participation in the study;\n* Male or Female, aged \\>18 years;\n* Availability of clinical data.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* B-ALL positive for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements.\n\nLow blast percentage (\\\u003C70%) samples could be excluded for molecular evaluations, not for cytofluorimetric analyses;",{"count":54,"type":21},60,"It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice, independently from the decision to include the patient in the study.",[27],[58,59,60],"lymphoblastic acute leukemia (LAL)","triple negative","B cell","2025-04-07",{"date":33,"type":36},{"date":64,"type":36},"2019-10-23",{"date":66,"type":21},"2026-01",{"name":68,"class":43},"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS",3]